What is Watchmaker Genomics?
Watchmaker Genomics is at the forefront of applying advanced enzymology to unlock breakthrough applications in DNA and RNA reading, writing, and editing. The company leverages its deep expertise in protein engineering, coupled with large-scale enzyme manufacturing capabilities, to meet the stringent quality, performance, and scalability demands of high-growth clinical genomics. This strategic positioning allows Watchmaker Genomics to address critical needs within the rapidly evolving genomics landscape.
How much funding has Watchmaker Genomics raised?
Watchmaker Genomics has raised a total of $40.1M across 2 funding rounds:
Debt
$150K
Series A
$40M
Debt (2020): $150K with participation from PPP
Series A (2022): $40M led by Decheng Capital and Eclipse Ventures
Key Investors in Watchmaker Genomics
Decheng Capital
Decheng Capital is a global investment firm established in 2012, specializing in providing capital and strategic support to early-stage life science companies and growth stage healthcare companies.
Eclipse Ventures
Eclipse Ventures is an investment firm that focuses on early-stage technology companies.
PPP
Public-Private Partnership
What's next for Watchmaker Genomics?
The substantial enterprise-level funding indicates Watchmaker Genomics is poised for significant scaling and expansion. This capital infusion is likely to accelerate product development, enhance manufacturing capacity, and broaden market reach, particularly within the clinical genomics sector. The company's focus on foundational enzymatic technologies suggests a trajectory aimed at becoming a key enabler for next-generation sequencing and gene editing applications, potentially driving further innovation and strategic partnerships in the life sciences industry.
See full Watchmaker Genomics company page
